Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006276 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Tolerability, and Safety Study of DFN-15
A Phase 3 study, sponsored by BioDelivery Sciences International.
- Completed
- Registry status
- Phase 3
- Development phase
- 622
- Enrollment target
NCT03006276: Completed Phase 3 study, sponsored by BioDelivery Sciences International.
NCT03006276 is a Phase 3 study that has completed, run by BioDelivery Sciences International. The registered enrollment target is 622 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006276, a Phase 3 study, has completed, sponsored by BioDelivery Sciences International.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 622 participants
- Enrollment target
Study Summary
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
Primary Outcome
Percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo in the DB1 period (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]) during DB1.
Interventions
- DRUG DFN-15 Active
- OTHER DFN-15 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
What the finished NCT03006276 record still lists
NCT03006276 is an interventional study that assigns participants to a tested intervention. The registered 622 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which DFN-15 Active is the first listed.
NCT03006276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03006276 about?
NCT03006276 is a clinical study titled "Efficacy, Tolerability, and Safety Study of DFN-15". Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
What is the current status of trial NCT03006276?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 622 participants. The study started on 2016-12. Estimated completion is 2019-05.
What interventions are being tested in trial NCT03006276?
The interventions under investigation include: DFN-15 Active (DRUG), DFN-15 Placebo (OTHER).
Who is sponsoring clinical trial NCT03006276?
This trial is sponsored by BioDelivery Sciences International, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03006276's enrollment target sits among peer trials
622 588th of 2000 higher than 1,413 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712355 · 621 participants · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia